Indicated for: type 2 diabetes mellitus
Substance: saxagliptin + metformin (DPP-4 inhibitor + biguanide antidiabetic)
ATC: A10BD10 (Alimentary tract and metabolism | Blood glucose lowering drugs, excl. insulins | Combinations of oral blood glucose lowering drugs)
Saxagliptin+metformin is a combination medication used in the treatment of type 2 diabetes mellitus. Saxagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases levels of active incretins, stimulating insulin secretion and reducing glucagon production. Metformin, a biguanide, reduces hepatic glucose production and improves glucose utilization by tissues.
This combination is taken orally, usually twice daily, and is indicated for patients who fail to control their blood sugar levels through diet, exercise, or monotherapy. It is effective in reducing glycated hemoglobin (HbA1c) levels and preventing diabetes-related complications.
Common side effects include nausea, diarrhea, upper respiratory tract infections, and headache. In rare cases, severe adverse reactions such as pancreatitis or lactic acidosis may occur. Regular monitoring of renal function and blood glucose levels is essential.
Saxagliptin+metformin is a valuable therapeutic option for patients with type 2 diabetes, offering improved glycemic control through complementary mechanisms of action.